Condition: Multidrug-resistant Tuberculosis · Pulmonary Tuberculosis · Tuberculosis · Sponsor: Institute of Tropical Medicine, Belgium
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB).
This description comes directly from the study's public registry record.
Natacha Herssens, MSc · 003232470778 · nherssens@itg.be
Tom Decroo, MD · 003232470535 · tdecroo@itg.be
Always discuss trial participation with your own doctor first.
| Damien Foundation | Niamey, Niger | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04260477